We would love to hear your thoughts about our site and services, please take our survey here.
Fevertreeman.
Having read your post I suspect you are unhappy with the CEO?
Your post IMHO leans slightly to you being a bit unhappy with Mr Newland?
Your post:-
==================================
Nero Newland has to be right up there along with one of the most geriatric useless boards of directors out there. He has burnt through millions of shareholders monies, consistently duped investors, been incapable of anything approaching proper commercial planning ahead of FDA, failed to build proper management bench, and hasnt met a single one of his targets bar getting FDA approval for just one indication! Instead, shareholders who own the company have been treated appallingly: a smoke screen of puffery (look at his ridiculous RNS at start of year) from Newland just can't hide the fact that (1) No signs of results or progress on Ovarian and Prostate trials that were promised before Xmas (2) Not a single commercial deal of any note ! in 10 months Newland has only inked 2 pathetically small deals (1) Artios in May which was so irrelevant it had no value attached and then (2) the miniscule Eisai pilot study worth a miserable £250k. Given Newlands run rate....we are likely to get a grand total of £250k extra in deals over next 10 months, missing his target of £6m by c £5.5m....and I agree the signs arent good when they have adverts to recruit salesmen. If the3se are first time posts wtf has Newland been doing all this time or even worse are they seeking repalcements existing staff who tiring of newland's nonsense have just upped and walked.
====================
LOL!
Erm... the ask has improved to 1.8p..........
Plus BIG oil, or should I say gas in this case will be watching developments here. Even if it is in Tanzania!
Announced on 2nd Jan. Eisai Inc. being one of the top 100 Plc's in Japan. It is the only way a Company doing a drug trial involving a cancer that has spread can monitor the cancers HER-2 status (or anything else they want to look at in a LIVE cancer cell) without doing a biopsy involving expensive and time consuming surgery. Surgery which may not even be possible dependant on where the cancer is and the health of the patient. Clearly getting the results from a simple blood test is a "no-brainer" as they say. More of these Co's need to start to use their brains I think! The Eisai Inc. contract hopefully will be the start of HUNDREDS and then THOUSANDS Of SIMILAR orders........................ It's a World wide market don't forget.
Extract:-
"ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce that it has signed a contract with the global pharmaceutical company, Eisai Inc. ("Eisai").
Under the agreement, in a pilot study worth US $250,000 to ANGLE, ANGLE will provide CTC analysis with its Portrait HER2 assay to assess breast cancer patients' HER2 (human epidermal growth factor receptor 2) status in a Phase II study of the HER2 targeting antibody-drug conjugate (ADC) BB-1701. Success in the pilot study offers the potential for multiple large scale follow-up studies.
ANGLE's Portrait HER2 assay enables quantitative assessment of both HER2 protein expression (via IF) and HER2/neu gene amplification (via FISH) to identify patients who could benefit from anti-HER2 ADC treatment. HER2-low breast cancer accounts for 55% of all breast cancer cases with analysts predicting that the global HER2+ breast cancer ADC market will reach US $3.3 billion per annum by 2030. Because of market expansion into HER2-low patients, ANGLE has developed a quantitative HER2 assay to enable accurate stratification of patient populations throughout the treatment pathway given HER2 status can change over time. ".
All IMHO.
Interesting. Money coming back to our sector then.
https://www.thisismoney.co.uk/money/markets/article-13154285/Halma-acquires-Dutch-based-Rovers-initial-73m-deal.html
Phenominal. The only way you can monitor a cancer that has already spread's status during a cancer treatment trial is by monitoring the cancer itself. This would involve surgery to remove a sample of the tumour for analysis. As Angle have repeatedly said this if often not even possible. Also, even if it is there is considerable cost involved in getting the patient back to the hopspital, possibly a general anesthetic, surgeons and nurses pay etc.. etc.. A lot of money. In fact a massive amount of time and money. Therefore the ONLY WAY to get this completely up to date information easily and relatively cheaply is to catch a circulating cancer cell using Angle's Parsortic machine and analyse that!!!!! As the cell has come off the tumour it has the information needed.
It's only a matter of time before thye penny drops with the thousands of Companies in the World doing this sort of trial.
As I keep saying I await the bid. 50p plus per share nailed on.
All IMHO.
Can't be long before the first flow test starts. Should be RNS to confirm any day.
Going forward. Loads in the pipeline.
You only have to look back at the RNS's in the last 6 months.
All IMHO.
Completing Next Generation Sequencing of DNA in cancer patients.
The next step IMHO is to add the ADDITIONAL information analysing LIVE circulating cancer cells (CCT's) caught using Angle's parsortix machine (see Angle's RNS's dated 2nd and 22nd Jan 2024). This would be for patients who have cancer that has spread which happens when CCT's get into the blood stream. This would give the "full picture" of how a cancer is or is not progressing and enable monitoring the effect of any treatment. Thus this could give information to say the treatment is working OR to indicate it is NOT working anabling a different treatment to be tried sooner.
Just waiting for the takeover bid........
Come on Illumina........... or Roche......... or etc..........................
https://www.youtube.com/watch?v=nO-HsxY1afo
All IMHO.
Completing Next Generation Sequencing of DNA in cancer patients.
The next step IMHO is to add the ADDITIONAL information analysing LIVE circulating cancer cells (CCT's) caught using Angle's parsortix machine (see Angle's RNS's dated 2nd and 22nd Jan 2024). This would be for patients who have cancer that has spread which happens when CCT's get into the blood stream. This would give the "full picture" of how a cancer is or is not progressing and enable monitoring the effect of any treatment. Thus this could give information to say the treatment is working OR to indicate it is NOT working anabling a different treatment to be tried sooner.
Just waiting for the takeover bid........
Come on Illumina........... or Roche......... or etc..........................
All IMHO.
LOL!
Up 4.82% now.
Now Angle and others have proved CtDNA simply does not contain all the information a circulating cancer cell (cct) can provide using Angle's Parsortix to obtain the cell FROM A standard BLOOD TEST I don't see how big pharma can ignore Angle any longer. The proof is in the RNS of 4th and 22nd Jan THIS YEAR. So we are just several weeks on and I suspect various Co's will be considersing making an offer for Angle Plc. The currect market cap is only 260,580.000 shares x 16p = £41,692,800. £41m is some sort of bad joke if you ask me.
I suspect we will get an offer more like 50p a share (260,580,000 x 50p = £130,290,000), for starters.
Angle simply do not have the financial muscle to realise the full potential of what they have which is quote incredible.
A large pharma Co. will do the math, buy them, invest and then make a killing as the saying goes.
All IMHO.
In and you will hear why Angle Plc are at the forefront.............................
Just waiting for the buyout. Could it end up being Roche??
https://www.youtube.com/watch?v=OKQGSuOuPkY
All IMHO.
Up 4.02%
Up 1.26%.
Forgot the link:-
More and more negative news about Boeing. I truly am shocked.
https://www.bbc.co.uk/news/business-68409029
Summit in San Diago, California by Brett Swansiger, Chief Commercial Officer, ANGLE Plc.
Our market was closed when the presentation was done as they are 8Hrs behind us.
Hopefully we will see some upward movement in the sp later when the usa market opens about 2:30 Pm.
Lots of extremely interesting other participants too!
See here:-
https://lbx-summit.com/about/agenda/day-one/
The cancer trial involves.
https://www.eisai.com/news/2023/news202330.html